Minna Balbas, PhD

Medical Writer Ultragenyx Pharmaceutical Inc. Novato, CA

Minna Balbas

Lab Phone

646-888-2163

Lab Fax

646-888-2595

Email

balbasm@sloankettering.edu

Dissertation

Mutation Based Resistance to Antiandrogens in Prostate Cancer (2013)

Mentor

Charles L. Sawyers, MD

Start Year

2009

End Year

2013

Education

University of California, Los Angeles

Publications

 

Balbas MD, Burgess MR, Murali R, Wongvipat J, Skaggs BJ, Mundel P, Weins A, Sawyers CL. (2014) MAGI-2 scaffold protein is critical for kidney barrier function. Proc Natl Acad Sci U S A., 111, 14876-81. PMCID: PMC4205655.

Arora V, Schenkein E, Murali R, Subudhi S, Wongvipat J, Balbas M, Shah N, Cai L, Efstathiou E, Logothetis C, Cheng D, Sawyers C. (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell, 155, 1309-1322.

Balbas M, Evans M, Hosfield D, Wongvipat J, Arora V, Watson P, Chen Y, Greene G, Shen Y, Sawyers C. (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife, 2, 1-21.

Watson P, Chen Y, Balbas M, Wongvipat J, Socci N, Viale A, Kim K, Sawyers C. (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A, 107, 16759-16765.

Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. (2008) Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell  14, 485-93.

 

Related topics:

Pictured: Charles Sawyers Research Suggests a New Approach for Overcoming Resistance to a Targeted Therapy for Prostate Cancer